FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Waldmeier

Research Profile

Living Beings

Anatomy

Chemicals & Drugs

Procedures

Electric Stimulation

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Vanita Chopra; Jonathan H Fox; Greg Lieberman; Kathryn Dorsey; Wayne R Matson; Peter Waldmeier; David E Housman; Aleksey G Kazantsev; Anne B Young; Steven M Hersch
A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Peter Waldmeier; Donna Bozyczko-Coyne; Michael Williams; Jeffry L Vaught
Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Michael Honer; Bastian Hengerer; Milen Blagoev; Samuel Hintermann; Peter Waldmeier; P August Schubiger; Simon M Ametamey
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Waldmeier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Vanita Chopra; Jonathan H Fox; Greg Lieberman; Kathryn Dorsey; Wayne R Matson; Peter Waldmeier; David E Housman; Aleksey G Kazantsev; Anne B Young; Steven M Hersch
A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(42):16685-9.
2006: Peter Waldmeier; Donna Bozyczko-Coyne; Michael Williams; Jeffry L Vaught
Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Biochemical pharmacology 2006;72(10):1197-206.
2006: Michael Honer; Bastian Hengerer; Milen Blagoev; Samuel Hintermann; Peter Waldmeier; P August Schubiger; Simon M Ametamey
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Nuclear medicine and biology 2006;33(5):607-14.
2006: Claire-Marie Vacher; Martin Gassmann; Sandrine Desrayaud; Etienne Challet; Amyaouch Bradaia; Daniel Hoyer; Peter Waldmeier; Klemens Kaupmann; Paul Pevet; Bernhard Bettler
Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice.
Journal of neurochemistry 2006;97(4):979-91.
2004: Magnus J Hansson; Gustav Mattiasson; Roland Månsson; Jenny Karlsson; Marcus F Keep; Peter Waldmeier; Urs T Ruegg; Jean-Maurice Dumont; Kamel Besseghir; Eskil Elmér
The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria.
Journal of bioenergetics and biomembranes 2004;36(4):407-13.
2003: Klemens Kaupmann; John Cryan; Petrine Wellendorph; Cedric Mombereau; Gilles Sansig; Klaus Klebs; Markus Schmutz; Wolfgang Froestl; Herman van der Putten; Johannes Mosbacher; Hans Bräuner-Osborne; Peter Waldmeier; Bernhard Bettler
Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice.
The European journal of neuroscience 2003;18(10):2722-30.
2000: Rolf Heumann; Christoph G Goemans; D Bartsch; K Lingenhöhl; Peter Waldmeier; Bastian Hengerer; Peter R Allegrini; K Schellander; E F Wagner; Thomas Arendt; R H Kamdem; K Obst-Pernberg; Frank Narz; Petra Wahle; Hartmut Berns
Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration.
The Journal of cell biology 2000;151(7):1537-48.
2000: Peter Waldmeier; Will Spooren; Bastian Hengerer
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(6):526-37.
1999: Will Spooren; Peter Waldmeier; Conrad Gentsch
The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine.
Journal of neural transmission (Vienna, Austria : 1996) 1999;106(9-10):825-33.
1998: Jennifer Ong; David I B Kerr; Helmut Bittiger; Peter Waldmeier; P A Baumann; N G Cooke; Stuart J Mickel; Wolfgang Froestl
Morpholin-2-yl-phosphinic acids are potent GABA(B) receptor antagonists in rat brain.
European journal of pharmacology 1998;362(1):27-34.
1998: Will Spooren; Annick Vassout; Peter Waldmeier; Conrad Gentsch
Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity.
European journal of pharmacology 1998;353(1):1-4.
1996: Peter Waldmeier; P Martin; K Stöcklin; C Portet; Markus Schmutz
Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum.
Naunyn-Schmiedeberg's archives of pharmacology 1996;354(2):164-72.
1996: A F Steulet; H J Mobius; Stuart J Mickel; K Stocklin; Peter Waldmeier
Determination of rat brain and plasma levels of the orally active GABAB antagonist 3-amino-propyl-n-butyl-phosphinic acid (CGP 36742) by a new GC/MS method.
Biochemical pharmacology 1996;51(5):613-9.
1995: Peter Waldmeier; P Wicki; W Fröstl; Helmut Bittiger; J J Feldtrauer; P A Baumann
Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release.
Naunyn-Schmiedeberg's archives of pharmacology 1995;352(6):670-8.
1995: Peter Waldmeier; P A Baumann; P Wicki; J J Feldtrauer; C Stierlin; Markus Schmutz
Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters.
Neurology 1995;45(10):1907-13.
1994: Peter Waldmeier; P Wicki; J J Feldtrauer; Stuart J Mickel; Helmut Bittiger; P A Baumann
GABA and glutamate release affected by GABAB receptor antagonists with similar potency: no evidence for pharmacologically different presynaptic receptors.
British journal of pharmacology 1994;113(4):1515-21.
1994: Peter Waldmeier; P Wicki
GABA release in rat cortical slices is unable to cope with demand if the autoreceptor is blocked.
Naunyn-Schmiedeberg's archives of pharmacology 1994;349(6):583-7.
1993: T Christen; P A Baumann; Peter Waldmeier
A role for computer simulation in solving the riddles of autoreceptor-mediated regulation of GABA release.
Naunyn-Schmiedeberg's archives of pharmacology 1993;348(6):618-27.
1993: A F Steulet; K Stöcklin; P Wicki; Peter Waldmeier
Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
Neurochemical research 1993;18(11):1131-6.
1993: Peter Waldmeier; P Wicki; J J Feldtrauer
Release of endogenous glutamate from rat cortical slices in presence of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid.
Naunyn-Schmiedeberg's archives of pharmacology 1993;348(5):478-85.
1993: Peter Waldmeier; C Hertz; P Wicki; C Grunenwald; P A Baumann
Autoreceptor-mediated regulation of GABA release: role of uptake inhibition and effects of novel GABAB antagonists.
Naunyn-Schmiedeberg's archives of pharmacology 1993;347(5):514-20.
1993: Peter Waldmeier; T Graf; M Germer; J J Feldtrauer; H Howald
Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Biological psychiatry 1993;33(5):373-9.
1993: Peter Waldmeier
Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Progress in neuro-psychopharmacology & biological psychiatry 1993;17(2):183-98.
1993: Peter Waldmeier; A Glatt; J Jaekel; Helmut Bittiger
Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.
Clinical neuropharmacology 1993;16 Suppl 2():S19-24.
1993: Annick Vassout; A Bruinink; J Krauss; Peter Waldmeier; S Bischoff
Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants.
Journal of receptor research 1993;13(1-4):341-54.
1992: Peter Waldmeier; K Stöcklin
Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.
European journal of pharmacology 1992;216(2):243-7.
1992: Peter Waldmeier; K Stöcklin; J J Feldtrauer
Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum.
Naunyn-Schmiedeberg's archives of pharmacology 1992;345(5):544-7.
1992: Peter Waldmeier; K Stöcklin; J J Feldtrauer
Systemic administration of baclofen and the GABAB antagonist, CGP 35348, does not affect GABA, glutamate or aspartate in microdialysates of the striatum of conscious rats.
Naunyn-Schmiedeberg's archives of pharmacology 1992;345(5):548-52.
1992: Peter Waldmeier; J J Feldtrauer; T Graf; H Howald
Brofaromine, a drug inhibiting MAO-A and 5-HT uptake.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():341A-342A.
1991: Peter Waldmeier
The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, gamma-butyrolactone and HA 966 on rat striatal dopamine synthesis.
Naunyn-Schmiedeberg's archives of pharmacology 1991;343(2):173-8.
1991: S Bischoff; J Krauss; C Grunenwald; F Gunst; M Heinrich; M Schaub; K Stöcklin; Annick Vassout; Peter Waldmeier; L Maître
Endogenous dopamine (DA) modulates [3H]spiperone binding in vivo in rat brain.
Journal of receptor research 1991;11(1-4):163-75.
1990: Peter Waldmeier; P A Baumann; J J Feldtrauer; K Hauser; Helmut Bittiger; S Bischoff; G von Sprecher
CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
Naunyn-Schmiedeberg's archives of pharmacology 1990;342(3):305-11.
1990: Peter Waldmeier; K Stöcklin
Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
European journal of pharmacology 1990;180(2-3):297-304.
1990: Peter Waldmeier; P A Baumann
Presynaptic GABA receptors.
Annals of the New York Academy of Sciences 1990;604():136-51.
1990: P A Baumann; P Wicki; C Stierlin; Peter Waldmeier
Investigations on GABAB receptor-mediated autoinhibition of GABA release.
Naunyn-Schmiedeberg's archives of pharmacology 1990;341(1-2):88-93.
1990: Peter Waldmeier; P De Herdt; L Maitre
Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.
Journal of neural transmission. Supplementum 1990;32():381-6.
1989: Peter Waldmeier; K Stöcklin
The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo.
European journal of pharmacology 1989;169(2-3):197-204.
1989: Peter Waldmeier; P Wicki; J J Feldtrauer; P A Baumann
Release of endogenous GABA from the substantia nigra is not controlled by GABA autoreceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1989;340(4):372-8.
1989: Peter Waldmeier; P Wicki; J J Feldtrauer; P A Baumann
Ca2+-dependent release of endogenous GABA from rat cortical slices from different pools by different stimulation conditions.
Naunyn-Schmiedeberg's archives of pharmacology 1989;339(1-2):200-7.
1988: Peter Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.
Naunyn-Schmiedeberg's archives of pharmacology 1988;337(6):609-20.
1988: Peter Waldmeier; P Wicki; J J Feldtrauer; P A Baumann
The measurement of the release of endogenous GABA from rat brain slices by liquid chromatography with electrochemical detection.
Naunyn-Schmiedeberg's archives of pharmacology 1988;337(3):284-8.
1988: Peter Waldmeier; P Wicki; J J Feldtrauer; P A Baumann
Potential involvement of a baclofen-sensitive autoreceptor in the modulation of the release of endogenous GABA from rat brain slices in vitro.
Naunyn-Schmiedeberg's archives of pharmacology 1988;337(3):289-95.
1988: A Delini-Stula; E Radeke; Peter Waldmeier
Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors.
Psychopharmacology series 1988;5():147-58.
1987: Peter Waldmeier; J J Feldtrauer
On the role of O-methylation in the metabolism of S-adenosylmethionine in rat brain.
Biochemical pharmacology 1987;36(17):2855-61.
1986: Peter Waldmeier; L Maître; P A Baumann; K Hauser; S Bischoff; Helmut Bittiger; R Paioni
Ifoxetine, a compound with atypical effects on serotonin uptake.
European journal of pharmacology 1986;130(1-2):1-10.
1986: H R Olpe; J Laszlo; Mario F. Pozza; P De Herdt; Peter Waldmeier; R S Jones
Glutamate-induced activation of rat locus coeruleus increases CA1 pyramidal cell excitability.
Neuroscience letters 1986;65(1):11-6.
1985: Peter Waldmeier; H Huber; M Heinrich; K Stoecklin
Discrimination of neuroleptics by means of their interaction with amfonelic acid: an attempt to characterize the test.
Biochemical pharmacology 1985;34(1):39-44.
1984: Peter Waldmeier; K F Tipton; R Bernasconi; A E Felner; P A Baumann; L Maitre
CGP 4718 A, a new potential antidepressant with a dual mode of action.
European journal of pharmacology 1984;107(1):79-89.
1984: Peter Waldmeier; P A Baumann; B Fehr; P De Herdt; L Maitre
Carbamazepine decreases catecholamine turnover in the rat brain.
The Journal of pharmacology and experimental therapeutics 1984;231(1):166-72.
1984: S Bischoff; Helmut Bittiger; J Krauss; Annick Vassout; Peter Waldmeier
Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment.
European journal of pharmacology 1984;104(1-2):173-6.
1984: R Ortmann; M Schaub; A Felner; J Lauber; P Christen; Peter Waldmeier
Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors.
Psychopharmacology 1984;84(1):22-7.
1984: P A Baumann; Peter Waldmeier
Negative feedback control of serotonin release in vivo: comparison of 5-hydroxyindolacetic acid levels measured by voltammetry in conscious rats and by biochemical techniques.
Neuroscience 1984;11(1):195-204.
1983: Peter Waldmeier; A E Felner; K F Tipton
The monoamine oxidase inhibiting properties of CGP 11305 A.
European journal of pharmacology 1983;94(1-2):73-83.
1983: Peter Waldmeier; J J Feldtrauer; K Stoecklin; E Paul
Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
European journal of pharmacology 1983;94(1-2):101-8.
1983: E Mogilnicka; C G Boissard; Peter Waldmeier; A Delini-Stula
The effects of single and repeated doses of maprotiline, oxaprotiline and its enantiomers on foot-shock induced fighting in rats.
Pharmacology, biochemistry, and behavior 1983;19(4):719-23.
1983: Peter Waldmeier; P A Baumann
Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
Naunyn-Schmiedeberg's archives of pharmacology 1983;324(1):20-6.
1983: Peter Waldmeier; K H Antonin; J J Feldtrauer; C Grunenwald; E Paul; J Lauber; P Bieck
Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.
European journal of clinical pharmacology 1983;25(3):361-8.
1983: Peter Waldmeier; A M Buchle; K Stoecklin; B Fehr; J J Feldtrauer
The effects of amfonelic acid on 5-HT metabolism in rat brain.
Journal of neural transmission 1983;57(3):149-65.
1983: Peter Waldmeier; P A Baumann; A Delini-Stula; R Bernasconi; K Sigg; O Buech; A E Felner
Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.
Modern problems of pharmacopsychiatry 1983;19():31-52.
1982: Peter Waldmeier; R Ortmann; S Bischoff
Modulation of dopaminergic transmission by alpha-noradrenergic agonists and antagonists: evidence for antidopaminergic properties of some alpha antagonists.
Experientia 1982;38(10):1168-76.
1982: Peter Waldmeier; P A Baumann; K Hauser; L Maitre; A Storni
Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer.
Biochemical pharmacology 1982;31(12):2169-76.
1982: L Maître; P A Baumann; J Jackel; Peter Waldmeier
5-HT uptake inhibitors: psychopharmacological and neurobiochemical criteria of selectivity.
Advances in biochemical psychopharmacology 1982;34():229-46.
1981: H R Olpe; R Ortmann; B Fehr; Peter Waldmeier
Experimentally induced supersensitivity of neocortical neurons to microiontophoretically administered serotonin.
Brain research 1981;224(2):367-74.
1981: P A Baumann; Peter Waldmeier
Further evidence for negative feedback control of serotonin release in the central nervous system.
Naunyn-Schmiedeberg's archives of pharmacology 1981;317(1):36-43.
1981: R Ortmann; S Martin; Peter Waldmeier
Supersensitivity to L-5-hydroxytryptophan after 5,7-dihydroxytryptamine injections in desmethylimipramine- and nomifensine-pretreated rats: behavioral evidence for postsynaptic supersensitivity.
Psychopharmacology 1981;74(2):109-14.
1980: R Ortmann; Peter Waldmeier; E Radeke; A Felner; A Delini-Stula
The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats.
Naunyn-Schmiedeberg's archives of pharmacology 1980;311(2):185-92.